Management of hepatitis C in patients with chronic kidney disease

Table 4 Studies on the treatment of chronic hepatitis C in kidney transplant recipients

Ref.	Year	n	Therapy	Interferon dose	Duration (mo)	SVR
Harihara et al[154]	1994	3	IFN	3-6 MU biw	NA	NA
Therret et al[155]	1994	13	IFN	3-5 MU tiw	About 4	NA
Magnone et al[156]	1995	11	IFN	1.5-5.0 MU tiw	6	NA
Rostaing et al[157]	1995	14	IFN	3 MU tiw	About 5	0%
Ozgür et al[158]	1995	5	IFN	4.5 MU tiw	6	NA
Yasumura et al[159]	1997	6	IFN	6 MU tiw	About 7	33%
Durlik et al[160]	1998	11	IFN	3 MU tiw	About 6	0%
Hanafusa et al[161]	1998	10	IFN	9 MU tiw	6	10%
Tokumoto et al[162]	1998	6	IFN	9 MU tiw	6	50%
Baid et al[163]	2003	12	IFN + RBV	3 MU tiw	Variable	33%
Tang et al[164]	2003	4	IFN + RBV	3 MU tiw	12	50%
Shu et al[165]	2004	11	IFN + RBV	1 MU tiw	12	27%
Izopet et al[166]	1997	15	IFN	3 MU tiw	About 5	0%
Sharma et al[167]	2006	6	IFN + RBV	3 MU tiw	About 12	33%
Pageaux et al[168]	2009	8	PEG-IFNα2a	180 μg qw	6-12	50%
Aljumah et al[169]	2012	19	PEG-IFN + RBV	90-180 μg qw	12	42%
Sanai et al[170]	2013	32	PEG-IFN + RBV	135-180 μg qw	12	38%

IFN: Interferon; MU: Million units; biw: Two times a week; NA: Not available; tiw: Three times a week; PEG-IFN: Pegylated interferon; RBV: Ribavirin; SVR: Sustained virological response rate by intention-to-treat analysis.